Derek is an IP litigator. His practice focuses on patent and other intellectual property cases across a variety of technologies, with an emphasis on the life sciences.
Derek’s practice encompasses all areas of litigation through trial and appeal, working as lead and Delaware counsel.
Derek has extensive experience with pharmaceutical cases, representing innovator companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman Act. Drawing upon his academic background in biochemistry and molecular biology, he also frequently represents companies in litigation involving biotechnologies such as nucleic acid sequencing and analysis platforms.
Represented UCB at trials in Hatch-Waxman cases concerning UCB’s Vimpat® epilepsy drug and Neupro® rotigotine transdermal system.
Represented Shire and Sanofi-Aventis at trial in Hatch-Waxman litigation related to Firazyr®, Shire’s treatment for hereditary angioedema (“HAE”).
Represented Sanofi at trials involving Multaq®, Sanofi’s treatment for atrial fibrillation among certain patients.
Represented Agilent Technologies Inc. in a patent case involving nucleic acid array genotyping technology.
Represented VANDA Pharmaceuticals in Delaware actions involving the drug Fanapt® for treatment of schizophrenia and Hetlioz® for the treatment of non-24-Hour Sleep Wake Disorder.
Represented Bayer in Delaware actions involving its medications Nexavar®, Stivarga®, and Xarelto®.
News & Insights
Professional & Civic
American Bar Association (Litigation and Intellectual Property Law Sections)
Federal Bar Association
Federal Circuit Bar Association
Delaware State Bar Association
Harvard Law School, JD, 2005,
Ethics, Law and Biotechnology (ELAB), president
Stanford University, MS, Biochemistry, 2001
Johns Hopkins University, B.A., Biology, 1997
- Delaware, 2005
- District of Columbia, 2008
- US District Court for the District of Delaware, 2006
- US Court of Appeals for the Federal Circuit, 2007